Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.
about
A conserved dileucine motif mediates clathrin and AP-2-dependent endocytosis of the HIV-1 envelope proteinEnhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239.The tale of the long tail: the cytoplasmic domain of HIV-1 gp41.Diversity of envelope genes from an uncloned stock of SIVmac251.Systematic analysis of intracellular trafficking motifs located within the cytoplasmic domain of simian immunodeficiency virus glycoprotein gp41Sensitive assays for simian foamy viruses reveal a high prevalence of infection in commensal, free-ranging Asian monkeys.Induction of antibody-mediated neutralization in SIVmac239 by a naturally acquired V3 mutation.Comparison of plasma viremia and antibody responses in macaques inoculated with envelope variants of single-cycle simian immunodeficiency virus differing in infectivity and cellular tropism.4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralizationIncreased infectivity in human cells and resistance to antibody-mediated neutralization by truncation of the SIV gp41 cytoplasmic tailPotent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo.Enhanced antagonism of BST-2 by a neurovirulent SIV envelopeQuantitative Correlation between Infectivity and Gp120 Density on HIV-1 Virions Revealed by Optical Trapping VirometryHighly complex neutralization determinants on a monophyletic lineage of newly transmitted subtype C HIV-1 Env clones from IndiaMapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding.Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors.Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques.Dense Array of Spikes on HIV-1 Virion Particles.Differential binding of neutralizing and non-neutralizing antibodies to native-like soluble HIV-1 Env trimers, uncleaved Env proteins, and monomeric subunits.The cholesterol-binding motif of the HIV-1 glycoprotein gp41 regulates lateral sorting and oligomerization.Infectivity and neutralization of simian immunodeficiency virus with FLAG epitope insertion in gp120 variable loops.Modeling how many envelope glycoprotein trimers per virion participate in human immunodeficiency virus infectivity and its neutralization by antibody.Truncating the Gp41 Cytoplasmic Tail of SIV Decreases Sensitivity to Neutralizing Antibodies without Increasing Envelope Content of Virions.High-Resolution Sequencing of Viral Populations During Early SIV Infection Reveals Evolutionary Strategies for Rapid Escape from Emerging Env-Specific Antibody Responses.Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.
P2860
Q24681865-5E4B0ACD-31A3-49FF-8910-CF7591220CE1Q33313394-789D00CE-6902-4D6A-9BD3-14B82D240716Q33402455-3EE71F8B-1E88-4534-83F8-BB99E13B4AE7Q34306883-8BAC0890-D711-4CF0-ABAB-6610609441F7Q34315382-51463A66-CD3E-4C22-8118-8CA9EEE582DEQ35494155-7CA64F23-E101-4DA6-AA10-977BC9F05051Q35914466-3F5690D3-15B3-44F9-A17F-3D9496E3AC1DQ35955770-06BCEBBB-455E-4E21-8283-48978AE562A2Q36423977-71C6EF55-718D-46E8-AD76-BDD7AA837534Q36483956-C8CE4437-BBA4-4B9B-B034-1E0EBA975D47Q36837815-F2DAA767-6EA7-4C52-A6A9-3D23F4E60DECQ36841032-E875FCA9-EDA5-48E3-B084-EAF23C312E3FQ36898925-427915A1-955C-44E3-B4E6-4F81CC12495AQ36951741-3312E8D4-3076-4DF0-97B9-534CE73FE4E5Q37065878-ECECBC1D-6550-45E4-BF81-F9389C63BBB2Q37179996-4FACBD24-37A1-4284-B2CD-F9003EF2AD49Q37240035-5F05DEDC-2C62-4D82-A30F-C9BD2D28A4A7Q37286064-856D3B14-5CE7-404E-8FE4-2B22D1AEBC75Q37530466-2CEA6929-1CFA-42F8-AEC2-1F168DBC8643Q38817990-9EDAACB6-1225-4519-9CD5-680520890F38Q38989507-AD773310-7E56-4C64-8A9F-81454BA97533Q38993416-AC182A91-634D-4FD9-A5D4-5A66794B5591Q40096483-35F6C933-1DC0-46AA-A412-5241FC7BEE77Q41967451-6CB535B6-14E5-450D-8482-DF6F66FE00B7Q47398548-3A636029-4984-49AC-B247-B6BAA390793FQ47552258-5544F278-CEB7-46D6-A7E2-DDB25A4F6277Q55508034-3DB3B5D8-E6F6-44C8-B3AE-6763A79BB55C
P2860
Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Virion envelope content, infec ...... simian immunodeficiency virus.
@ast
Virion envelope content, infec ...... simian immunodeficiency virus.
@en
type
label
Virion envelope content, infec ...... simian immunodeficiency virus.
@ast
Virion envelope content, infec ...... simian immunodeficiency virus.
@en
prefLabel
Virion envelope content, infec ...... simian immunodeficiency virus.
@ast
Virion envelope content, infec ...... simian immunodeficiency virus.
@en
P2093
P2860
P1433
P1476
Virion envelope content, infec ...... simian immunodeficiency virus.
@en
P2093
Eloísa Yuste
George N Pavlakis
Ronald C Desrosiers
Welkin Johnson
P2860
P304
12455-12463
P356
10.1128/JVI.79.19.12455-12463.2005
P407
P577
2005-10-01T00:00:00Z